Aptamer Group Secures Second Optimer Development Programme with Unilever

Deodorant Wars: Aptamer Doubles Down with Unilever

Well now, this is a proper sequel worth paying attention to. Aptamer Group (AIM: APTA) just dropped news of a second act in their Unilever collaboration – and frankly, it smells like progress. The synthetic binder specialists have secured a follow-up Optimer development programme with the consumer goods behemoth, complete with another six-figure paycheque. Let’s unpack why this matters beyond the undisclosed sum.

The Nitty-Gritty: What’s Actually Happening?

Aptamer’s diving back into the science of stink. Their new mission? Develop a fresh panel of Optimer binders targeting a different biological pathway linked to body odour formation. Essentially, they’re engineering molecular “keys” to lock down malodour mechanisms. This isn’t just repetition; it’s a strategic expansion. If the first programme tackled one bacterial enzyme villain, this sequel targets another – giving Unilever a potential second weapon in their deodorant arsenal.

Why This Isn’t Just a Rerun

Three things make this genuinely intriguing:

• Validation via Velocity: The fact Unilever came back for more before the first programme even finished on-person trials speaks volumes. Optimers from Round 1 have already passed internal validation and lab testing at both companies. That’s a solid vote of confidence.
• Market Muscle Meets Niche Tech: Unilever isn’t just playing in the deodorant space – it dominates 30% of the global market (leaving competitors trailing at ~10%). With the sector growing at ~4.5% CAGR, Aptamer’s tech isn’t just innovative; it’s potentially plugged into a revenue geyser.
• Platform Flex: This cements Optimer’s leap from therapeutic/diagnostic niches into mass-market consumer health. Bindings molecules in your Dove stick? That’s serious scalability.

The Strategic Scent Trail

Look beyond the lab coats. Aptamer’s playing a clever long game here. CEO Arron Tolley’s mention of building “multiple, licensable assets” with a “global powerhouse” is the real headline. This isn’t just fee-for-service income (though welcome, I’m sure). It’s about:

• Proof of Concept Amplified: Two programmes = stronger evidence of Optimer’s versatility in cosmetics.
• Future Royalty Streams: Successful on-person trials could lead to licensing deals – the holy grail of recurring revenue.
• Cross-Sector Beacon: Success here shouts to other FMCG giants: “This works. Want some?”

Leadership Lingo: Reading Between the Lines

The quotes tell their own story. Unilever’s Senior VP R&D, Dr Sam Samaras, calling Aptamer’s team “world class” and highlighting “encouraging results” isn’t corporate fluff. It’s rare for giants to publicly praise small-caps like this. Tolley’s palpable excitement about “deepening partnership” suggests Unilever isn’t just a client – it’s becoming a strategic springboard.

The Bottom Line for Investors

This second contract reinforces three bullish signals:

1. Reduced Risk: Repeat business from a blue-chip de-risks the tech’s applicability.
2. Market Expansion: Personal care is a vast, untapped frontier for Aptamer beyond pharma.
3. Execution Credibility: They’re delivering milestones that make partners commit further capital.

The real catalyst? Watch for results from those 2025 on-person trials from Programme 1. If Optimers perform on skin like they do in labs, Aptamer’s not just fighting odour – it’s building a formidable, licensable IP portfolio inside a £100bn+ FMCG giant. Now that’s what I call a sticky partnership.